Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
Salvatore Brugaletta, Associate Professor of Medicine at University of Barcelona, shared on LinkedIn about a recent article he and his colleagues co-authored, published in BMJ Heart, adding:
”Twelve months DAPT starts to be too long as compared to a strategy of short DAPT in ACS patients.
While earlier aspirin discontinuation may be associated with greater net clinical benefit owing to reduced bleeding, 3- month DAPT may be associated with more favourable ischaemic outcomes, underscoring the importance of individualising DAPT duration according to bleeding and ischaemic risk.”
Title: Optimal timing of aspirin discontinuation after acute coronary syndrome treated with percutaneous coronary intervention: a systematic review and meta-analysis
Authors: Kamil Bujak, Claudio Laudani, Riccardo Rinaldi, Paweł Łajczak, Mariusz Gąsior, Natalia Pawlas, Luis Ortega-Paz, Manel Sabate, Salvatore Brugaletta
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience